Jacobs Levy Equity Management’s Cogent Biosciences COGT Stock Holding History

Jacobs Levy Equity Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Buy	+50,156	New	+$1.75M	0.01%	600
2025 Q4	–	Sell	-187,083	Closed	-$2.69M	–	946
2025 Q3	$2.69M	Buy	+187,083	New	+$2.22M	0.01%	535
2019 Q4	–	Sell	-8,249	Closed	-$48K	–	1006
2019 Q3	$48K	Sell	8,249 -2,945	-26%	-$23.9K	﹤0.01%	903
2019 Q2	$117K	Sell	11,194 -16,075	-59%	-$214K	﹤0.01%	911
2019 Q1	$479K	Buy	27,269 +14,970	+122%	+$256K	0.01%	780
2018 Q4	$216K	Buy	+12,299	New	+$364K	﹤0.01%	861

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jacobs Levy Equity Management's COGT Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 50,156 shares worth $1.94M. The stake represents 0.01% of the portfolio and ranks #600 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in COGT as recently as Q3 2025.

Jacobs Levy Equity Management first reported a position in COGT in Q4 2018 and has held it in 6 quarters since. The position peaked at $2.69M in Q3 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Jacobs Levy Equity Management held 50,156 shares of Cogent Biosciences worth $1.94M as of Q2 2026.
Cogent Biosciences was a new Jacobs Levy Equity Management position in Q2 2026.
Cogent Biosciences made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #600 holding.
Jacobs Levy Equity Management first reported a position in Cogent Biosciences in Q4 2018 and has held it in 6 quarters since.
Jacobs Levy Equity Management's Cogent Biosciences position peaked at $2.69M in Q3 2025.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.